• Ludvik



    Read more

    Ludvik Sandnes


    Ludvik Sandnes has more than 40 years of experience from international corporate finance, asset management and investment banking from Norfund, The Royal Bank of Scotland, BDO Noraudit, PwC Financial Advisors, Christiania Bank, UNI Storebrand, Orkla Borregaard, Den Norske Creditbank and Statoil. Current board positions include: Oslo Cancer Cluster, IC-T AS, Pre-Diagnostics AS and Pioner Fonds AS. He has a Bachelor of Commerce and a degree as Certified European Financial Analyst (AFA) from the Norwegian School of Economics and Business Administration, NHH. Mr. Sandnes is a Norwegian citizen, and resides in Bærum, Norway.

  • Jean-Pierre


    Read more

    Jean-Pierre Bizzari

    Jean-Pierre Bizzari, M.D., served as Executive Vice-President, Group Head, and Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015. He has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Revlimid®, Vidaza®, Abraxane®, Irinotecan® (CPT-11). As a world-renowned oncology expert, he is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee. Mr. Bizzari is also an active board member in various biotech companies, such as Transgene in France, Halozyme Therapeutics and Celator Pharmaceuticals in the US. He has published more than 70 articles in peer-reviewed journals and more than 160 abstracts in scientific congresses. Mr. Bizzari joined the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). He then joined Rhône-Poulenc Rorer in 1993 as Vice President of Clinical Oncology, based in Paris and moved to Collegeville (PA – USA) in 1997. From 2002 until 2008, Mr. Bizzari served as Vice President of Clinical Oncology Development at Sanofi-Aventis in Malvern, PA before joining Celgene. Jean-Pierre Bizzari holds a medical degree specialized in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal Mac Gill Cancer Center in Canada.

  • Joanna


    Read more

    Joanna Horobin

    Ms Horobin has comprehensive experience within the biopharmaceutical industry. She is currently Senior Vice President, Chief Medical Officer and a Member of the Leadership Team at Idera Pharmaceuticals, Inc. in Cambridge, MA, USA. Ms Horobin’s current role includes the development and regulatory strategy as well as the execution of the clinical trial programme for the company's pipeline of novel oligonucleotides for the treatment of rare oncology and other indications.

    Prior to this position, she was CMO of Verastem, Inc. and CEO of Syndax Pharmaceuticals. Additionally, Ms Horobin has held several roles of increasing responsibility at global pharmaceutical companies such as Rhône Poulenc Rorer (now Sanofi) where she led the global launch of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer. Ms Horobin also led a successful joint venture with Chugai to launch Granocyte® (lenograstim) and played significant leadership roles in the approvals of several successful products.

  • Per


    Read more

    Per Samuelsson

    Per Samuelsson is a partner at Odlander Fredrikson/HealthCap, the life sciences venture capital firm, which he joined in 2000. Prior to this, he gained more than 15 years of investment banking experience, mainly with Aros Securities in Sweden. In his final position with Aros Securities, as a Director in the firm’s corporate finance department, he specialised in the areas of merger transactions, initial public offerings, and equity incentive programmes. Prior to this, Mr. Samuelsson was Head of Research, also at Aros Securities. Current board positions include: BioStratum, Oncopeptides, Nordic Vision Clinics, RSPR, SwedenBIO and Targovax. Mr. Samuelsson is a Swedish citizen, and resides in Sweden.

  • Gisela


    Read more

    Gisela Schwab

    Gisela M. Schwab, M.D., has served as Executive Vice President and Chief Medical Officer since January 2008 of Exelixis, Inc. She joined Exelixis in 2006 as Senior Vice President and Chief Medical Officer. From 2002 to 2006, she held the position of Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. She also served as Vice President, Clinical Development at Abgenix from 1999 to 2001. Prior to working at Abgenix, from 1992 to 1999, she held positions of increasing responsibility at Amgen Inc., most recently as Director of Clinical Research and Haematology/Oncology Therapeutic Area Team Leader. From August 2011 to July 2014, Dr. Schwab has served as a member of the Board of Directors of Topotarget A/S, a publicly-held biopharmaceutical company. Current board position: Cellerant Therapeutics, Inc. She received her Doctor of Medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute, Bethesda Maryland, USA, and is board certified in internal medicine and haematology and oncology. She is a German citizen, and resides in the U.S.
  • Hilde

    Hermansen Steineger

    Read more

    Hilde Hermansen Steineger

    Dr. Hilde Hermansen Steineger, PhD, is Head of Innovation Management at Pronova BioPharma ASA / BASF, a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products. Previously, Hilde Steineger was VP Investor Relations and Communications at Pronova BioPharma and prior to that she was Senior Associate with Neomed Management, an international investment firm focusing on the healthcare and life science industry. From 2004 to 2006, she worked as an independent advisor focusing on start-ups within the Life Science/Health Care sector, and before that, she was an equity analyst at Kreditkassen (now part of Nordea Markets) based in Oslo and Copenhagen (2001-2004). Hilde Steineger began her professional career at Nycomed Pharma, where she worked in the area of clinical research and international marketing from 1999 to 2001. Current board positions include: Strongbridge BioPharma and PCI Biotech. She holds a BSc and a PhD in Medical Biochemistry from the University of Oslo. Dr. Steineger is a Norwegian citizen, and resides in Norway.